Humacyte, Inc. — 2021 Form 10-K Summary
Business context and period. This annual report covers the fiscal year ended December 31, 2021. Humacyte is a clinical-stage biotechnology company developing bioengineered human acellular vessels (HAVs); it has no approved products and has generated no product revenue. The August 2021 merger with Alpha Healthcare Acquisition Corp. was accounted for as a reverse recapitalization, so pre-merger results are those of Legacy Humacyte.
Key financial results
| Metric | 2021 | 2020 |
|---|---|---|
| Grant revenue | $1.3 million | $1.5 million |
| Research and development expense | $61.3 million | $54.1 million |
| General and administrative expense | $21.1 million | $12.0 million |
| Operating loss | $81.2 million | $64.6 million |
| Net loss | $26.5 million | $66.5 million |
| Net cash used in operating activities | $81.2 million | $55.6 million |
- Revenue was grant-funded, not product sales; operating margins are not meaningful for a pre-commercial company.
- Net loss narrowed mainly because of a $55.8 million non-cash gain from remeasuring the merger earnout liability and $3.3 million of PPP loan forgiveness. These items do not reflect improved operating performance; operating loss increased 26%.
- Cash and cash equivalents were $217.5 million and short-term investments were $8.0 million at year-end, totaling $225.5 million. Working capital was $218.3 million. Management expected available cash and investments to fund operations for at least 12 months from the filing date.
- Financing cash flow included $242.4 million of merger and PIPE proceeds and $29.7 million of net loan proceeds. Investing cash use was $8.2 million, primarily for certificates of deposit.
- The company had $30.0 million principal outstanding under a term loan facility of up to $50.0 million. Interest was 7.5% at year-end; the remaining $20.0 million was conditional on milestones. The loan is secured by substantially all assets other than intellectual property. Finance lease obligations totaled $23.1 million.
- Year-end liabilities included a $103.7 million contingent earnout liability, measured using Level 3 inputs. The company reported total assets of $286.5 million and stockholders’ equity of $122.2 million.
Material changes and operating developments
- R&D expense rose 13%, principally due to higher personnel costs and spending on clinical studies and commercial-scale manufacturing development. General and administrative expense rose 76%, including public-company, merger, staffing and stock-compensation costs.
- The August 2021 merger and PIPE financing materially changed the capital structure: Legacy Humacyte preferred shares converted to common shares, and the combined company received $242.4 million in net merger and PIPE proceeds.
- Eight commercial-scale LUNA200 manufacturing systems were installed and operational, with reported gross annual capacity of approximately 7,200 HAVs. The FDA authorized LUNA200-produced HAVs for ongoing trials after comparability work; commercial use would still require approval.
- In the V006 Phase III dialysis-access trial, HAV did not meet the pre-specified secondary-patency non-inferiority endpoint at 24 months. Reported secondary patency was 67% for HAV versus 74% for ePTFE at 24 months; non-inferiority was demonstrated at 12 months, not 24 months. HAV had fewer conduit infections in the trial.
- As of year-end, approximately 471 patients had received HAVs across indications. The V005 vascular-trauma trial had enrolled 47 patients against an estimated target of approximately 75; V007 dialysis-access enrollment was 207 of a 240-patient target.
Outlook, commentary and risks
- Management planned to submit a BLA for vascular trauma in 2022 or 2023 and for dialysis access in 2023, subject to trial results, FDA discussions and manufacturing review. These are plans, not guaranteed dates. The filing provides no financial guidance or expected product revenue forecast.
- Management expects continued operating losses and negative operating cash flow while it advances trials, prepares for potential commercialization and scales manufacturing. Additional capital may be needed; no committed external funding beyond the loan facility was identified.
- Key risks include clinical or regulatory failure or delay, the V006 efficacy result, enrollment and follow-up challenges, manufacturing scale-up and comparability, reliance on single-source suppliers, COVID-19 effects, reimbursement uncertainty, and dependence on Fresenius Medical Care for specified international rights and U.S. commercialization collaboration.
- Fresenius Medical Care holds exclusive development rights outside the U.S. and EU and commercialization rights outside the U.S. for the specified 6 mm HAV and indications; the company retains U.S. commercialization responsibility and shares a portion of U.S. net sales under the agreement.
- The company reported no legal proceedings management believed would have a material adverse effect. Disclosure controls were deemed effective at year-end; management did not provide an ICFR assessment in this 10-K under the reverse-acquisition transition relief. The filing also discusses AHAC’s prior warrant-accounting restatement and related control weakness.
Important facts for investors to verify
- Current FDA feedback on V005’s trial size and design, final enrollment, results, and the timing and evidence required for a trauma BLA.
- How the V006 24-month endpoint miss affects the dialysis-access regulatory path, and the results and completion timing of V007.
- Whether LUNA200 manufacturing remains comparable and can reliably supply trials and potential commercial demand at acceptable cost.
- Cash burn, capital spending, debt terms and milestone availability, and whether the stated runway remains adequate as trials and commercialization preparations progress.
- Reimbursement prospects and the practical economics and execution of the Fresenius Medical Care agreement, including partner obligations and termination rights.